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Background
Lupus nephritis (LN) is the major determinant of out-
come in pediatric Systemic Lupus Erythematosus (pSLE)
and its treatment remains a challenge. Aim. To report
the experience of our centre in treating with Rituximab
(RTX) SLE patients with severe LN.
Methods
Four pSLE patients with, refractory to conventional
immunosuppressive treatment, biopsy-proven LN
received four doses of 375-500mg/m
2 RTX, 2-3 weeks
apart. All patients were concurrently on corticosterois
(CSs) and mycophenolate mofetil. Patients’ clinical and
laboratory findings were recorded at RTX initiation,
after each infusion and at 3.4±2.1 month-intervals there-
after. pSLE activity was assessed using the European
Consensus Lupus Activity Measurement (ECLAM),
while LN activity using 24-hour urine protein excretion
and serum cystatin C.
Results
Patients were followed-up for 6-21 months (median: 16
months). Full Β cell depletion was noticed 2-4 weeks
after RTX initiation and lasted 4-7 months. All patients
achieved complete LN remission 3.5 months (range: 2-
4) after RTX initiation which was retained in 3 patients
through the follow-up period. One patient relapsed 15
months after RTX initiation and received one additional
RTX dose. ECLAM scores and CSs doses were markedly
reduced in all patients, while complement levels
increased. No side effects or infections were observed.
Conclusion
RTX is an alternative, safe and efficient treatment for
refractory LN.
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